At present, standard first-line treatment for patients with metastatic colorectal cancer (mCRC) includes combination chemotherapy in conjunction with either an anti-epidermal growth factor receptor (EGFR) agent such as cetuximab [1], [2] or panitumumab [3], or an antiangiogenic agent, such as bevacizumab [4]–[6]. Here, EGFR is linked to metastatic colorectal cancer.